Biotechnology company Moderna Inc (Nasdaq:MRNA) reported on Thursday the receipt of an emergency use authorization (EUA) for COVID-19 Vaccine Moderna from the Qatar Ministry of Public Health.

The COVID-19 vaccine's approval is based on the scientific evidence, including a data analysis from the pivotal Phase 3 clinical study announced in November. Qatar has secured access to COVID-19 Vaccine Moderna under a supply agreement announced in October 2020.

In addition, Moderna has received authorization for its COVID-19 vaccine from health agencies in the US, Canada, Israel, the EU, the UK, Switzerland and Singapore. It is working with additional health agencies and with the World Health Organization on the authorization of its vaccine in respective jurisdictions.

According to the company, the COVID-19 Vaccine Moderna is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed with National Institute of Allergy and Infectious Disease's (NIAID) Vaccine Research Centre.